Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca’s Imfinzi has been approved by the European Union as the first perioperative immunotherapy for muscle-invasive bladder cancer, based on the NIAGARA Phase III trial results. This approval is expected to transform the standard of care in Europe, offering a significant reduction in disease recurrence and extending survival rates, thereby setting a new benchmark for treatment in this area.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and recent strategic corporate events drive a favorable outlook. Technical indicators suggest potential for upward momentum. Although the stock’s valuation appears high, the robust earnings call and dividend support a solid investment case.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a leading biopharmaceutical company specializing in the development of innovative medicines, particularly in the field of oncology. The company focuses on immuno-oncology, aiming to redefine cancer care through its comprehensive portfolio of immunotherapies designed to stimulate the immune system to attack tumors.
Average Trading Volume: 2,524,459
Technical Sentiment Signal: Hold
Current Market Cap: £161.1B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.